720 results on '"Diab, Adi"'
Search Results
152. 397 Intra-tumor immunotherapy injections utilizing image guidance in interventional radiology: clinical trial experience at a tertiary care cancer center
153. 657 Interleukin-6 receptor blockade for management of immune checkpoint inhibitor related adverse events in patients with melanoma
154. 368 REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors
155. 638 Plasma proteome analysis in patients with immune checkpoint inhibitors related arthritis and pneumonitis
156. 311 Phase II trial of lymphodepletion plus adoptive cell transfer with or without dendritic cell vaccination in patients with metastatic melanoma
157. 658 Toxicities of single agent and combination immune checkpoint inhibitors in patients with pre-existing autoimmune diseases
158. Abstract A13: Clinical characteristics of responders to nivolumab plus ipilimumab (Nivo/Ipi) in metastatic uveal melanoma
159. Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design
160. Abstract A09: Characteristics of uveal melanoma patients with central nervous system metastases
161. Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma
162. AML-314: Post-Transplant Cyclophosphamide Reduces the Incidence of Acute Graft Versus Host Disease in AML/MDS Patients Who Receive Checkpoint Inhibitors After Allogeneic Stem Cell Transplant
163. Abstract CT134: Tilsotolimod engages the TLR9 pathway to promote antigen presentation and Type-I IFN signaling in solid tumors
164. Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)
165. Assessment of Image-Guided Intratumoral Delivery of Immunotherapeutics in Patients With Cancer
166. Abstract D075: Investigating the immuno-biology underlying differential response to immunotherapy in White and non-White patients with metastatic acral melanoma
167. Intratumor immunotherapy utilizing real time radiological image guidance: Early experience from a tertiary cancer center.
168. Safety results from phase I/II study of the PI3Kβ inhibitor GSK2636771 (G) in combination with pembrolizumab (P) in patients (pts) with PD-1 refractory metastatic melanoma (MM) and PTEN loss.
169. Radiomic signatures to predict response to targeted therapy and immune checkpoint blockade in melanoma patients (pts) on neoadjuvant therapy.
170. Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma
171. Circulating Tumor Cells and Early Relapse in Node-positive Melanoma
172. P860 Results from a combination of OX40 (PF-04518600) and 4–1BB (utomilumab) agonistic antibodies in melanoma and non-small cell lung cancer in a phase 1 dose expansion cohort
173. Melanoma of the External Auditory Canal: A Review of Seven Cases at a Tertiary Care Referral Center
174. Trends in PRO reporting in clinical trials leading to cancer immunotherapy drug approvals from 2011 to 2019.
175. Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti‐CTLA4 and anti‐PD1 combination immunotherapy: Incidence, management, and clinical benefit.
176. Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns.
177. Aberrant DNA Methylation Predicts Melanoma-Specific Survival in Patients with Acral Melanoma
178. Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation–Related Abscopal Responses
179. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial
180. Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series
181. Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy
182. Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti–PD‐1 in patients with metastatic melanoma
183. Abstract 941: B cells are required to generate optimal antitumor immunity in response to PD-1 blockade treatment
184. Abstract 2838: The gut microbiome (GM) and immunotherapy response are influenced by host lifestyle factors
185. Abstract 1493: Therapeutic efficacy and tolerability of combined immune checkpoint blockade in metastatic melanoma patients is influenced by the gut microbiome
186. Abstract 4062: Activation of innate and adaptive immunity using intratumoral tilsotolimod (IMO-2125) as monotherapy in patients with refractory solid tumors: a phase Ib study (ILLUMINATE-101)
187. Corrections to: Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature
188. IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy
189. THU0656 IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH CANCER AND RHEUMATOLOGIC DISEASES: A SYSTEMATIC REVIEW OF THE LITERATURE
190. A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors
191. Phase II trial of nab-paclitaxel (ABI) and ipilimumab (ipi) in patients with treatment naïve metastatic melanoma.
192. ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy.
193. Phase II study of ipilimumab and nivolumab (ipi/nivo) in metastatic uveal melanoma (UM).
194. Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab.
195. CA045-001: A phase III, randomized, open label study of bempegaldesleukin (NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients (pts) with previously untreated, unresectable or metastatic melanoma (MEL).
196. Lymphodepletion (LD), tumor-infiltrating lymphocytes (TIL) and high (HD-IL2) versus low-dose (LD-IL2) IL-2 followed by pembrolizumab (pembro) in patients (pts) with metastatic melanoma (MM).
197. Genetic determinants of adverse events in cancer patients receiving immune checkpoint inhibitors.
198. A phase II study of oral azacitidine (CC-486) in combination with pembrolizumab (PEMBRO) in patients (pts) with metastatic melanoma (MM).
199. Standard-dose pembrolizumab (pembro) plus alternate-dose ipilimumab (ipi) in advanced melanoma: Initial analysis of KEYNOTE-029 cohort 1C.
200. Interleukin-6 is potential target to de-couple checkpoint inhibitor-induced colitis from antitumor immunity.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.